The Oncology Insights Gap: Why Traditional Market Research Misses What Drives Oncology Drug Adoption
Oncology brand leaders are surrounded by data. Long before a therapy reaches the market, teams invest heavily in segmentation studies, physician surveys, advisory boards, payer research, and forecasting models to predict uptake and reduce launch risk.
And yet, even with all of that rigor, many oncology brands encounter the same frustration once they’re in market: access is secured, awareness is high, but real-world adoption doesn’t move the way the models predicted.
This disconnect is the result of an insights gap, one that traditional market research was never designed to close.
Why Oncology Utilization Is So Hard to Capture on Paper
Oncology adoption doesn’t happen at the level of individual intent. It happens inside health systems, where care delivery is shaped by a web of treatment pathways, access controls, operational constraints, pharmacy workflows, staffing realities, and financial pressures.
Most research methodologies break these perspectives apart. A physician survey captures clinical preference. A payer interview captures coverage logic. A pharmacy discussion surfaces access mechanics. Each is valuable on its own, but none reflect how oncology care is actually implemented in practice.
Real-world adoption is a system behavior. It emerges from how clinical, operational, and financial factors interact inside a specific health system environment. This interaction is difficult to capture through static research alone.
Where Traditional Research Falls Short
Physicians participating in research often answer questions in a clinical vacuum: Would you prescribe this therapy? Where would you use it in the line of treatment?
Their answers are thoughtful, informed, and sincere. But they don’t always reflect the realities that shape day-to-day practice. Treatment pathways may not be updated quickly. Pharmacy teams may face capacity constraints. Utilization management requirements may introduce friction. Site-of-care considerations may influence where, and whether, a therapy is used.
These dynamics rarely surface in surveys or advisory boards. They surface later, when utilization data reveals that adoption has stalled.
The Perspective Pharma Rarely Hears Enough
Oncology service line leaders operate at the intersection of clinical care, pharmacy, finance, and operations. They are responsible for translating strategy into real-world implementation across networks and sites of care.
They see where adoption slows despite strong evidence. They understand how pathway governance, access requirements, and operational pressures influence prescribing behavior. They know which barriers clinicians may not raise in formal research, but factor into everyday decisions.
For pharma brand leaders, this provider-validated perspective explains not just what utilization looks like, but why it behaves the way it does.
Why Timing Matters More Than Ever
Today’s oncology environment is shaped by rapid therapeutic innovation, tighter access controls, and increasing system-level pressure. Adoption decisions are made faster, across more stakeholders, with less tolerance for misalignment.
At the same time, internal complexity and portfolio breadth mean pharma teams rely more heavily on external insight to understand how health systems are responding in real time.
In this environment, insights that arrive after adoption stalls are no longer insights. They're diagnostics.
Why the Oncology Forum Is Different
Most research looks backward. Many industry events prioritize exposure. The Oncology Forum is designed for something different: early, candid insight from the oncology service line leaders who shape real-world adoption.
The Oncology Forum is a closed-door, peer-level environment where leaders discuss how clinical pathways are governed, how access dynamics create friction or opportunity, and what health systems need to efficiently adopt and sustain new therapies.
For pharma teams, that means:
Hearing how adoption decisions are actually made inside health systems
Understanding where real-world adoption accelerates or stalls
Gaining unfiltered perspective on prescribing behavior and implementation challenges
Aligning strategy with how decisions unfold across service lines and sites of care
This is the type insight that static research methodologies are not designed to surface.
Closing the Insights Gap
The oncology brands that succeed are not just those with strong data. They are the ones that understand how health systems function beneath the surface and adjust accordingly.
Closing the oncology insights gap requires more than research. It requires proximity to the leaders shaping adoption in real time.
With a strict 1:1 health system–to–industry ratio, reserve your exclusive seat at our upcoming Oncology Forum to engage directly with oncology service line executives in a closed-door, peer-level setting designed for candid, strategic dialogue on what drives sustainable adoption across health systems.